JPMorgan Chase & Co. Issues Positive Forecast for Omnicell (NASDAQ:OMCL) Stock Price

Omnicell (NASDAQ:OMCL) had its price target upped by JPMorgan Chase & Co. from $37.00 to $44.00 in a research report released on Thursday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

A number of other research analysts also recently commented on OMCL. Craig Hallum increased their price objective on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Benchmark reiterated a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. Bank of America reiterated a “neutral” rating and issued a $57.00 target price (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Finally, Wells Fargo & Company raised their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $52.00.

Omnicell Price Performance

OMCL traded down $0.51 during trading on Thursday, hitting $43.60. The company had a trading volume of 33,248 shares, compared to its average volume of 536,197. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.74. The company has a market cap of $2.02 billion, a PE ratio of -113.10, a P/E/G ratio of 35.67 and a beta of 0.81. The business has a 50-day moving average of $44.22 and a 200-day moving average of $37.25.

Hedge Funds Weigh In On Omnicell

A number of institutional investors and hedge funds have recently bought and sold shares of OMCL. GAMMA Investing LLC raised its stake in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after buying an additional 553 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after acquiring an additional 1,000 shares during the period. 1620 Investment Advisors Inc. increased its stake in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after acquiring an additional 1,542 shares during the period. EntryPoint Capital LLC increased its stake in Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after acquiring an additional 1,345 shares during the period. Finally, CWM LLC increased its stake in Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after acquiring an additional 1,236 shares during the period. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.